RedHill Biopharma Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About RedHill Biopharma
Pharmaceutical Preparations, SIC 2834
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of pharmaceuticals for gastrointestinal diseases, infectious diseases, and oncology. The company commercializes Talicia, an FDA-approved delayed-release oral capsule indicated for the treatment of Helicobacter pylori infection in adults. It also develops a clinical-stage pipeline of therapeutic candidates, including opaganib and RHB-107, addressing viral infections, inflammatory conditions, and various cancers for adult patients and global healthcare markets.
The company conducts commercial activities primarily in the United States and has out-licensed products across international markets, including the United Arab Emirates and other Gulf Cooperation Council territories. Its U.S. commercial operations operate out of Raleigh, North Carolina, and had two employees as of year-end 2025. RedHill Biopharma Ltd. maintains its corporate headquarters and principal executive offices in Tel-Aviv, Israel.
Summary of the business section of RedHill Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RedHill Biopharma Ltd.
- Founded
- 2009
- Headquarters
- Tel Aviv, L3
- Address
- 21 Ha'Arba'A Street 64739
- Phone
- 972-3-541-3131
- Website
- redhillbio.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Auditor
- Kesselman & Kesselman, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- RDHL
- Exchange
- Nasdaq
- IPO date
- Jan 7, 2013
- Shares outstanding
- 50.92B, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-25 reverse, Aug 20, 2024; 1-for-40 reverse, Mar 23, 2023
- SEC CIK
- 1553846
- CUSIP
- 757468301
- ISIN
- US7574683014
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dror Ben-Asher | Chief Executive Officer, Director | 441,350,000 |
| Rick D. Scruggs | Chief Commercial Officer, Director | 312,500,000 |
| Gilead Raday | Chief Operating Officer | 218,780,000 |
| Adi Frish | Chief Corp & BD Officer | 276,810,000 |
| Guy Joel Goldberg | Chief Business Officer | 305,720,000 |
| Razi Ingber | Chief Financial Officer | 277,560,000 |
| Ofer Tsimchi | Director | 146,250,000 |
| Kenneth Reed | Director | 105,200,000 |
| Shmuel Cabilly | Director | 105,200,000 |
| Roni Mamluk | Director | 103,500,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 13 employees, of which 11 provide services in Israel and 2 provide services in the U.S.”